Itron Inc. filings document the reporting, governance and capital-structure records of an operating company serving utility and city infrastructure markets. Recent 8-K disclosures cover operating results, financial-condition updates, material agreements and the issuance of convertible senior notes, including purchase agreement and indenture terms tied to the company’s debt and equity structure.
Proxy and shareholder-vote filings describe director elections, advisory executive-compensation votes and annual meeting matters for holders of Itron common stock. Other material-event filings record cybersecurity response and operational-continuity disclosures, while exchange-registration information identifies ITRI common stock, no par value, as listed on the Nasdaq Global Select Market.
Itron, Inc. has expanded its Board of Directors by appointing Scott Drury as a new director. The board action is described in an amendment dated August 20, 2025, reflecting a change in the company’s leadership structure at the board level.
Mr. Drury has also been appointed to the Board’s Nominating and Corporate Governance Committee, which oversees board composition and governance practices. The filing is executed on behalf of the company by Senior Vice President, General Counsel and Corporate Secretary Christopher E. Ware.
Joan S. Hooper, SVP & CFO of Itron, Inc. (ITRI), reported a routine sale of 970 shares of common stock on 08/25/2025 at a price of $125.3071 per share. The filing states the shares were sold automatically to cover tax withholding obligations tied to the vesting of a restricted stock unit award. After the transaction, Ms. Hooper beneficially owns 88,394 shares directly. The Form 4 was signed by an attorney-in-fact on 08/26/2025. No other transactions, derivative positions, or additional material disclosures are included in this filing.
Itron director and President & CEO Thomas Deitrich reported a sale and ongoing ownership in Itron, Inc. The filing shows a sale of 1,786 shares on 08/25/2025 to cover tax withholding for vested restricted stock units at an average price of $125.3071 per share. After the sale, Mr. Deitrich directly beneficially owns 262,738 shares and indirectly holds 25,000 shares through a trust. The Form 4 was signed by an attorney-in-fact on 08/26/2025. The filing documents an insider liquidity event tied to RSU vesting rather than an open-market disposition initiated for other purposes.
John F. Marcolini, identified as SVP, Networked Solutions of Itron, Inc. (ITRI), reported a transaction on 08/25/2025 in which 565 shares of ITRON common stock were sold at $125.3071 per share. The Form 4 explains these shares were automatically sold to cover tax withholding for vested restricted stock units. After the sale, Mr. Marcolini beneficially owned 14,396 shares of Itron common stock, held directly. The filing was executed by an attorney-in-fact, Christopher E. Ware, on 08/26/2025.
Patrick Justin K, identified as SVP, Device Solutions and an officer of ITRON, INC. (ITRI), reported a sale of 388 shares of common stock on 08/25/2025 at a price of $125.3071 per share, resulting in 20,761 shares beneficially owned following the transaction. The Form 4 specifies the sale code as S and explains the shares were automatically sold to cover tax withholding obligations tied to the vesting of a restricted stock unit award. The filing was signed by attorney-in-fact Christopher E. Ware on 08/26/2025.
Itron, Inc. (ITRI) insider transaction: Laurie Ann Pulatie-Hahn, Senior Vice President, HR, reported a sale of 110 shares of ITRON common stock on 08/25/2025 at an average price of $125.3071 per share. After the sale, she beneficially owns 22,109 shares directly. The filing states the 110 shares were automatically sold to cover tax withholding tied to the vesting of a restricted stock unit award. The Form 4 was submitted and signed by an attorney-in-fact on 08/26/2025.
Insider sale to cover tax withholding on RSU vesting. David Marshall Wright, VP, Corporate Controller & CAO of Itron, Inc. (ITRI), reported a disposition of 106 shares of Itron common stock on 08/25/2025 at a reported price of $125.3071 per share. After the transaction he beneficially owned 7,685 shares directly. The filing states the shares were "automatically sold to cover tax withholding obligations" associated with the vesting of a restricted stock unit award. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Itron Inc. (ITRI) Form 144 notice reports a proposed sale of 110 common shares through Fidelity Brokerage Services with an aggregate market value of $13,783.78 and approximately 45,717,933 shares outstanding. The shares were acquired on 08/22/2025 through restricted stock vesting and paid as compensation. The filer, identified in the sale history as Laurie A. Hahn, sold 107 shares on 05/27/2025 for $12,299.13 and 78 shares on 08/11/2025 for $9,722.43. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Form 144 filed for Itron, Inc. (ITRI) reports a proposed sale of 106 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $13,282.56 and an approximate sale date of 08/25/2025 on NASDAQ. The 106 shares were acquired on 08/22/2025 via restricted stock vesting and were paid as compensation. The filer also reported a prior sale in the past three months of 102 shares on 05/27/2025 for gross proceeds of $11,724.40. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.
Summary of Form 144 for Itron, Inc. (ITRI)
This notice reports a proposed sale of 351 shares of ITRI common stock by an insider through Fidelity Brokerage Services on 08/25/2025 with an aggregate market value of $43,982.79. The shares were acquired via restricted stock vesting on 08/22/2025 and were issued as compensation. The filing shows 45,717,933 shares outstanding for the class. The filer sold 339 shares on 05/27/2025 for $38,966.39. The notice includes the standard insider representation that no undisclosed material adverse information is known.